Sharon Johnson, senior vice president, Global Quality & Regulatory Affairs, will head the organization.

The new flow sensors, BioPAT Flow, enable precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.

The manufacture and scale up production mark a significant milestone in the commercialization route of Nanobiotix lead product, NBTXR3.

WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.

Kite Pharma announced that it acquired T-Cell Factory B.V. in an effort to strengthen its T-cell portfolio.

NSF's consensus-based standard incorporates multiple regulatory and industry requirements into a single rigorous standard for the manufacturing and distribution of pharmaceutical excipients.

Penn Pharma's equipment addition meets growing need for continuous dry granulation and for handling of highly potent drugs.

Valeant announced that it would increase its original acquisition agreement with Salix to approximately $15.8 billion.

Remsima has demonstrated comparability to the reference product, Remicade, in terms of safety, efficacy, and quality.

BIO and the Colorado BioScience Association urge Colorado Governor Hickenlooper to sign a bill that will help patients gain access to interchangeable biologic products following FDA approvals.

The company will build an R&D team to find promising drug targets with genetic information submitted by customers in its database.

Drug spending rose last year at the highest rate since 2003, driven by specialty medicines, according to a report from pharmacy benefit manager Express Scripts.

Zogenix agreed to sell Zohydro, its controversial pain medication, to Pernix for $100 million.

Dr. Reddy’s announced that it expanded its facilities to include a formulation development laboratory at its Miyapur, Hyperabad, India plant.

Astellas Pharma announced that it received FDA approval for its treatment of fatal invasive fungal infections in patients with blood cancers.

Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.

The agency will employ a ring vaccination method similar to the one used to eradicate smallpox.

In a landmark decision, FDA approved Zarxio, making it the first biosimilar product in the United States.

Baxter has bought SuppreMol, a German biopharmaceutical company that focuses on autoimmune treatments, for €200 million ($225 million USD).

BASF is expanding its Verbund site in Ludwigshafen to include production capacity for about 20 specialty amines.

AbbVie’s acquisition of Pharmacyclics establishes the combined company as an emerging leader in hematological oncology.

Survey reveals pharmaceutical and medical attitudes towards “KOL” terminology.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Teva announced that it would sell its Sellersville, Pennsylvania facility to G&W Laboratories.

Canon announced that it established Canon BioMedical, a wholly owned biomedical business to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform.

Steve Nole joins Grand River Aseptic Manufacturing as director of manufacturing.

WellSpring Pharma Services has announced the appointment of David Mayers as president.

A facility expansion adds space for production of Repligen’s tangential flow system.